Skip to main content

Houston Primed for Life Sciences Boom

Published Nov 17, 2022 by A.J. Mistretta

Texas Medical Center Drone Shot

HOUSTON (November 17, 2022) – The Greater Houston Partnership commissioned Newmark Consulting Group to conduct a study, sponsored by San Jacinto College, Lone Star College, Houston Community College, and McCord Development, focused on assessing the Houston region’s existing resources and value proposition in the life sciences industry. 

Findings identified Houston’s industry-leading expertise in cell and gene therapy, biologic drug development, and molecular diagnostics; a continuous flow of new talent from regional universities; an emerging and robust commitment by community colleges to support two-year degree pathways to meet industry demands and the ability for life science companies to grow and thrive in the market. The study also identified strategic next steps for the Houston region to capitalize on these advantages. 

“The Newmark study confirms what we knew to be true about the potential for life sciences growth in Houston,” said Susan Davenport, Chief Economic Development Officer of the Greater Houston Partnership. “The study will help us coalesce our regional partners around a cohesive strategy to grow and expand the industry in Houston.”

Home to nearly 700 life science companies, Houston consistently ranks as a top-15 market for life sciences employment nationwide and first in Texas. Houston benefits from the densest patient population in the world, allowing for transformational clinical applications. With Houston’s robust and diverse workforce, an extensive university ecosystem and education infrastructure, along with world class research institutions, Houston is primed to capture extensive subsector gains. 

Houston ranks second in the nation in clinical trial volume, with more than 4,600 currently active clinical trials, representing 15% of all active U.S. trials. Houston-area institutions received $864.1 million in National Institutes of Health (NIH) grant funding, up 16.3% from 2020. In the last five years, the region received nearly $3.9 billion in NIH funding, an average of $740.7 million per year. Supported by the world-class institutions that comprise the Texas Medical Center and Houston’s sizeable patient population, expansive opportunities exist for commercial synergies with leading healthcare providers in the region. 

As a hub for translational and clinical research and pharmaceutical and medical device manufacturing, Houston is home to more than 26,000 non-healthcare life science employees. Houston’s robust life sciences workforce ranks 12th in the nation, on par with numbers reported for Research Triangle Park. Additionally, Houston compares favorably given its central U.S. location, ample space available and under construction throughout the region, a business friendly environment including accelerated development timelines, and the logistics benefits of  two international airports and the Port of Houston. 

The study finds Houston has the elements necessary to attract key subsectors of the life sciences industry, particularly in cell and gene therapy manufacturing; molecular diagnostics; and biologics drug development and manufacturing.

The study also identifies specific strategies to optimize the region’s “go-to-market” plan to attract more companies in this highly competitive industry.  

These recommendations include accelerating workforce development programs to produce new graduates in key life sciences occupations, refining Houston’s marketing messages to highlight the region’s existing life sciences” assets and activities within life science R&D and manufacturing.  Finally, the study identified the need to develop a shared regional strategy to attract and retain leading life sciences companies. 

The Partnership has assembled task forces to implement the recommendations, which will be led by the organization’s Life Sciences Committee, chaired by Ferran Prat, Senior Vice President of Industry Relations and Research at MD Anderson Cancer Center.

###

Greater Houston Partnership
The Greater Houston Partnership works to make Houston one of the best places to live, work and build a business. As the economic development organization for the region, the Partnership champions growth across 12 counties by bringing together business and civic-minded leaders who are dedicated to the area’s long-term success. Representing 950 member organizations and approximately one-fifth of the region’s workforce, the Partnership is the place companies come together to make an impact. Learn more at Houston.org.

Contact: 
A.J. Mistretta
amistretta@houston.org 
504-450-3516

Related News

Health Care

University of Houston, Baylor College of Medicine to Launch Cutting-Edge Research Hub

8/26/24
The University of Houston (UH) and Baylor College of Medicine (BCM) have been awarded a $44.2 million grant from the National Center for Advancing Translational Research. This funding will support the establishment of a regional hub dedicated to advancing clinical and translational research.  Dubbed the Consortium for Translational and Precision Health (CTPH), the new hub will enhance collaboration between the two institutions and other clinical and research groups within the Texas Medical Center. The CTPH aims to expedite the translation of new technologies and discoveries into patient care and real-world impact, provide funding and resources to accelerate pilot projects and research initiatives and connect investigators with local healthcare organizations and government agencies that are dedicated to healthcare, clinical research and policy.  “Research is the engine empowering health care’s life-changing advancements,” said UH President Renu Khator, in a release. “This innovative hub will be a catalyst for groundbreaking discoveries and treatments that improve people’s quality of life. That’s what drives us at UH and we’re ecstatic to cofound a regional hub for change alongside Baylor.”  The hub will be led by BCM’s Christopher Amos, professor and director of the Institute for Clinical and Translational Research, and Dr. Fasiha Kanwal, professor of medicine and chief of the section of gastroenterology and hepatology, alongside UH’s Dr. Bettina M. Beech, clinical professor of population health and chief population health officer.  “The CTPH is a partnership that draws on strengths of both institutions, creating a rich multidisciplinary environment. It will act as the vehicle to enhance the infrastructure and resources needed to effectively conduct research and implement solutions to advance healthcare,” said Dr. Carolyn Smith, interim senior vice president and dean of research at BCM. “It will help implement and create ongoing core research activities that will support the clinical translational science at both institutions.”  This strategic partnership comes at a time when local institutions are intensifying efforts to advance critical research that will deliver vital healthcare solutions. The University of Texas MD Anderson Cancer Center and Rice University recently announced a collaboration to advance fundamental and translational cancer research and develop life-saving technologies. Additionally, a research initiative led by Rice University, in collaboration with MD Anderson, received an $18 million grant to improve tumor removal technology for breast, head and neck cancer.  Learn more about Houston’s Life Sciences industry. 
Read More
Life Sciences

Rice University Awarded $18 Million to Advance Tumor Removal Technology

8/16/24
A research initiative led by Rice University, in collaboration with The University of Texas MD Anderson, has received an $18 million grant from the Advanced Research Projects Agency for Health (ARPA-H). The funding, which will be distributed over five years, will support the development of a new system aimed at enhancing the accuracy of tumor removal in breast, and head and neck cancer.   Rice University was among eight institutions chosen to receive a share of the $150 million in grants announced earlier this week by the Biden-Harris administration. This funding is part of the ongoing Cancer Moonshot initiative, which seeks to halve the cancer death rate by 2047.   The Rice and MD Anderson research team has developed a groundbreaking cancer pathology system called AccessPath, which addresses a significant challenge surgeons face: accurately identifying the margin where a tumor ends, and healthy tissue begins. Leveraging advanced technologies, including a high-resolution microscope and advanced artificial intelligence algorithms, AccessPath enables surgeons to determine in real time whether they have completely removed a tumor during surgery.  “Because of its low cost, high speed, and automated analysis, we believe AccessPath can revolutionize real-time surgical guidance, greatly expanding the range of hospitals able to provide accurate intraoperative tumor margin assessment and improving outcomes for all cancer surgery patients,” Rebecca Richards-Kortum, a lead researcher on the project and director of the Rice360 Institute for Global Health Technologies, said in a news release.  According to ARPA-H, nearly two million Americans are diagnosed with cancer each year. Given the complexity and high cost of cancer treatment, AccessPath offers a promising solution by “reducing the number of repeat interventions, lowering cancer care costs and improving patient outcomes,” said Dr. Ana Paula Refinetti, an associate professor in the Breast Surgical Oncology department at MD Anderson and one of the lead researchers on the project.  This cutting-edge innovation stems from a strategic partnership established this summer between Rice University and MD Anderson. Through the Cancer Bioengineering Collaborative, the two institutions are working together to develop life-saving technologies and bioengineering strategies to enhance cancer research, diagnosis and treatment.  “AccessPath is exactly the kind of life-changing research and health care innovation we are proud to produce at Rice, where we’re committed to addressing and solving the world’s most pressing medical issues,” said Ramamoorthy Ramesh, Rice’s executive vice president for research. “Partnering with MD Anderson on this vital work underscores the importance of such ongoing collaborations with our neighbors in the world’s largest medical center.”  This award is yet another example showcasing Houston’s leadership in advancing critical, life-saving technologies.  Learn more about Houston’s life sciences industry. 
Read More

Related Events

Economic Development

Life Sciences and Biotechnology Forum

The synthetic biology market, driven by research and development, is expected to grow significantly, with estimates suggesting it could reach $30 billion or more by 2030. Synthetic biology has the potential to…

Learn More
Learn More
Executive Partners